Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 2
Submit an article Journal homepage
1,516
Views
45
CrossRef citations to date
0
Altmetric
Reviews

Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future

Marc BernsCenter for Inflammatory Bowel Diseases, Melvin and Bren Simon Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, USACorrespondence[email protected]
&
Daniel W. HommesCenter for Inflammatory Bowel Diseases, Melvin and Bren Simon Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, USA
Pages 129-143 | Received 11 Sep 2015, Accepted 26 Nov 2015, Published online: 08 Jan 2016

References

  • Papers of special note have been highlighted as
  • either of interest (•) or of considerable interest
  • (••) to readers.
  • Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumor necrosis factor alpha in chronic inflammatory bowel disease. Gut. 1993;34:1705–1709.
  • Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 1993;94:174–181.
  • van Deventer SJ. Tumor necrosis factor and Crohn’s disease. Gut. 1997;40:443–448.
  • Derkx B, Taminiau J, Radema S. Tumour-necrosis-factor antibody treatment in Crohn’s disease. Lancet. 1993;342:173–174.
  • van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–135.
  • Stasi R, Amadori S, Newland AC, et al. Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma. 2005;46:509–516.
  • Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease: Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035.
  • Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–818.
  • Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
  • Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
  • Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
  • Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
  • Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.
  • Schreiber S, Khalig-Kareemi M, Lawrence IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250.
  • Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323–1332.

•• CZP lacks apoptotic and cytotoxic actions due to the absence of the Fc antibody region.

  • Tracey D, Klareskog L, Sasso E, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharma and Ther. 2008;117:244–279.
  • Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol. 2000;164:6193–6198.
  • Nesbitt AM, Fossati G, Dt B. Comparison of certolizumab pegol, etanercept, adalimumab, and infliximab: effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes. Am H Gastroenterol. 2006;101:S420–70.
  • Kirchner S, Holler E, Haffner S, et al. Effect of different tumor necrosis factor TNF reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokiune. 2004;28:67–74.
  • Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21:251–258.
  • Katz LH, Kopylov U, Fudim E, et al. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn’s disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol. 2014;38:491–498.
  • Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory response by outside-to-inside signal through transmembrane TNF-α. Gastroenterology. 2005;128:376–392.
  • Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn’s disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;163:1081–1090.
  • Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal. 2012;24:1297–1305.
  • Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206–211.
  • Oikonomopoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013;14:1421–1432.

•• A summary of anti-TNF-α mechanisms of action in IBD.

  • van den Brande JM, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn’s disease. Gut. 2007;56:509–517.
  • Sipos O, Torok A, Kalic T, et al. Reverse signaling contributes to control of chronic inflammation by anti-TNF therapeutics. Antibodies. 2015;4:123–140.
  • Waetzig GH, Rosenstiel P, Arlt A, et al. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autorince transforming growth factor- β1. FASEB J. 2005;19:91–93.
  • Sandborn WJ, Lee SD, Randall C, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014;40:903–916.
  • Arora T, Padaki R, Liu L. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45:124–131.
  • Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–1257.
  • Vande Casteele N, Gils A. Pharmacokinetics of ant-TNF monoclonal antibodies in inflammatory bowel disease: addaing value to current practice. J Clin Pharmacol. 2015;55:S39–50.
  • Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20:vi3–9.
  • Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946–964.
  • Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents [excludes infection and malignancy]. Gastroenterol Clin North Am. 2014;43:543–563.
  • Choquette D, Faraawi RY, Njoya M, et al. What are the implications of concomitant and pre-medication on infusion reactions to infliximab: results from “RemiTRAC Infusion”, a prospective real-world community registry. Arthritis Rheum. 2013;65(Suppl 10):452.
  • Miehsler W, Novacek G, Wenzl H, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221–256.
  • Vermeire S, Van AG, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol. 2009;23:101–112.
  • O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1–6.
  • Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608.
  • Vande Casteele N, Breynaert C, Vermeire S, et al. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay. Aliment Pharmacol Ther. 2011;34(401–3): 404–405.
  • Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomised controlled trial. Gastroenterology. 2003;124:917–924.
  • Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–1324.
  • Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.
  • Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468.
  • Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
  • Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196–212.
  • Keane J, Gershon S, Wise RP, et al., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–1104.
  • Afif W, Loftus EV Jr. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94:115–133.
  • Askling J, Fored CM, Brandt L, et al Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986–1992.
  • Wolfe F, Michaud K, Anderson J, et al Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372–379.
  • Murdaca G, Spano F, Ctatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14:571–582.

• This review covers infection risks associated with anti-TNF-α use.

• Meta-analysis of safety an efficacy of anti-TNF-α treatment in CD.

  • Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014;109:212–223.
  • Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146:941–949.

•• This paper provides evidence that anti-TNF-α therapy with concomitant immunomodulator treatment increases the risk of malignancy in CD patients.

  • Lee J, Clarke K. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. Int J Colorectal Dis. 2015. [Epub ahead of print]
  • Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–399.
  • Nardone B, Hammel JA, Raisch DW, et al. Melanoma associated with tumor necrosis factor-α inhibitors: a Research on Adverse Drug events and Reports (RADAR) project. Br J Dermatol. 2014;170:1170–1172.
  • Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939. DOI:10.1136/bmj.f1939.
  • West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:1122–1126.
  • Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–1640.
  • Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30.
  • Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578–585.
  • Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies corss-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1172–1183.
  • Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3–10.
  • Baert F, Kondraqunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn’s patients receiving maintenance adalimumab therapy: a post hoc analysis of the Kamiris trial. Gut. 2015. doi:10.1136/gutjnl-2014-307882.
  • Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315–329.
  • Rivkin A. Certolizumab pegol for the management of Crohn’s disease in adults. Clin Therp. 2009;31:1158–1176.
  • Ben-Horin S, Mazor Y, Yanai H, et al. The decline of anti-drug antibodies titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther. 2012;35:714–722.
  • Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient 2013. Am J Gastroenterol. 2013;108:962–971.
  • Krieckaert C, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12:217.
  • Vermeire S, Norman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–1231.
  • Ben-Horin S, Chowers Y. Loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987–995.
  • Suzuki Y, Matsui T, Ito H, et al. Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn’s disease: a prospective trial. Inflamm Bowel Dis. 2015;21:2114–2122.
  • Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721–1727.
  • Hibi T, Sakuraba A, Watanabe M, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol. 2014;49:254–262.
  • Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613–623.
  • Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92–101.
  • Gagniere C, Beaugerie L, Pariente B, et al. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn’s disease. J Crohns Colitis. 2015;9:349–355.
  • Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist’s perspective. Curr Opin Rheumatol. 2014;26:347–353.
  • Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174.
  • Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846–1854.
  • Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res. 2014;6:431–443.
  • van der Valk ME, Mangen M-J-J, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63:72–79.

• This study analyzes the current healthcare utilization and establishes anti-TNF-α therapy as the primary cost driver for the treatment of inflammatory bowel disease.

•• This review provides in depth knowledge about the infliximab biosimilar CT-P13.

•• CT-P13 shows comparable clinical efficacy and safety compared to originator infliximab.

  • 2014 annual report on form 10-K and 2015 proxy statement. AbbVie Inc. North Chicago, IL: AbbVie Inc., 2015. Available at: http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-reportsannual [Last accessed 12 August 2015].
  • Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2015. doi:10.1111/1756-185X.12711.
  • Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Sci. 2007;10:405–410.
  • Shealy D, Cai A, Staquest K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010;2:428–439.
  • Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95.
  • Ben-Bassat O, Iacono A, Irwin SP, et al. Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn’s Disease: Open Label Experience. Gastroenterology. 2012;142:S804.

•• A study demonstrating golimumab’s clinical efficacy in refractory CD patients.

• These preliminary findings of oral anti-TNF-α AVX-470 show positive results in UC patients.

  • Bhol KC, Tracey DE, Lemos BR. AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2013;19:2273–2281.
  • Vandepapeliere P, Malan F, Rogler G, et al. Safety, immunogenicity and clinical Phase I–II results of TNFα-kinoid immunotherapeutic in Crohn’s disease patients. Gastroenterology. 2011;140:S123.

•• This paper establishes TNF-K’s ability to induce anti-TNF-α antibodies that provide clinically significant response rates in CD patients.

  • Michelsen KS, Wong KG, Ko B, et al. HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses. Inflamm Bowel Dis. 2013;19:151–164.
  • Sandborn WJ, Targan SR, Byers VS, et al. Andrographis panciulata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013;108:90–98.

• A randomized, double-blind, placebo controlled study demonstrating superior clinical response rates in UC to HMPL-004 nonbiologic anti-TNF-α versus placebo.

  • Tang T, Targan SR, Li SZ, et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011;33:194–202.
  • Shelton E, Allegretti JR, Stevens B, et al. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis. 2015. [ Epub ahead of print].
  • Wei Y, Zhu W, Gong J, et al. Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract. 2015;2015:517597.

•• Fecal microbiota transplantation is a nondrug intervention that can provide clinically significant improvements for IBD patients.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.